Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status:
Completed
Trial end date:
2018-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of
sorafenib and temsirolimus will have on thyroid cancer. Treatment guidelines from the
National Comprehensive Cancer Network include sorafenib as a treatment option for thyroid
cancer.
Temsirolimus is an intravenous medication that is FDA approved for other type of cancers. In
laboratory studies, the addition of temsirolimus to sorafenib works better than sorafenib
alone.